Intervention

Berberine

Last updated Sat May 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

RCT evidence— Multiple small RCTs vs. placebo; some vs. metformin

What it is

Berberine is the yellow alkaloid in goldenseal, barberry, Oregon grape, and Coptis chinensis. Used in Chinese and Ayurvedic medicine for centuries, primarily for diarrhoea.

Evidence

HbA1c reductions ~0.7–1.0% in T2D RCTs (comparable to metformin in head-to-head trials, smaller sample sizes than diabetes-drug RCTs).
LDL reductions ~20% (works via PCSK9 mRNA destabilisation and LDLR upregulation).
Triglycerides down ~30% in dyslipidaemic cohorts.
Microbiome: shifts toward more SCFA-producing taxa.
Weight: modest loss in obese subjects.

Mechanism

AMPK activation (direct, mitochondrial complex I inhibition similar to metformin).
LDL receptor upregulation in liver.
Gut microbiome remodelling.
Glucose absorption reduction.

Not Ozempic

Berberine produces meaningful but modest effects (~5% weight loss optimistically, ~0.7% HbA1c). GLP-1 agonists like semaglutide deliver 15–25% weight loss and ~2% HbA1c reduction with established cardiovascular outcomes data. The "nature's Ozempic" framing is marketing.

Drug interactions

Berberine strongly inhibits CYP3A4, CYP2D6, P-gp. Major interactions with statins, calcineurin inhibitors, many psychiatric meds, anti-rejection drugs. Check with a pharmacist if on prescriptions.

References

Yin, J., Xing, H. & Ye, J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism 57, 712–717 (2008).